Monitor for future equity grant disclosures under the expanded plan, which could signal hiring or retention activity. The say-on-pay vote of 71% is supportive but not overwhelming — watch for any shareholder engagement follow-up in the next proxy statement.
Price Chart
Executive Summary
Filana Therapeutics held its 2026 Annual Meeting on June 11, 2026, where shareholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares by 4 million (from 5M to 9M) and extending the plan term to January 31, 2030. Three director nominees were re-elected, Ernst & Young was ratified as auditor, and the say-on-pay proposal passed with 71% of votes cast in favor. This is a routine governance filing with no material financial impact.
Key Facts
- Shareholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5,000,000 to 9,000,000.
- Plan term extended by two years through January 31, 2030.
- Amendment explicitly prohibits repricing, replacing, or cash-out of stock options or SARs without stockholder approval.
- Maximum annual limit on non-employee director compensation was decreased (both shares and dollar value).
- Maximum annual limit on equity awards to individuals in any single fiscal year was decreased.
- Three director nominees (Richard J. Barry, Pierre Gravier, Claude Nicaise) were re-elected with 85%, 87%, and 86% of votes cast, respectively.
- Ernst & Young LLP ratified as independent auditor for FY2026 with 22,671,610 votes for, 1,408,513 against, 479,653 abstain.
- Say-on-pay proposal passed with 7,487,142 for (71%), 2,827,840 against (27%), 100,494 abstain.
- Quorum achieved with 24,559,776 shares represented (51% of 48,307,896 entitled shares).
Financial Impact
No material financial impact. The 4M share increase under the equity plan represents potential future dilution of ~8.3% of current outstanding shares (48.3M), but no immediate issuance or cash flow effect.
Risk Factors
- Potential future dilution from up to 4M additional shares authorized under the equity plan.
- Say-on-pay support at 71% leaves room for potential future dissent if compensation practices change.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-020562 |
| Document: sava20260610_8k.htm | 0001437749-26-020562 |
| Document: 0001437749-26-020562-index-headers.html | 0001437749-26-020562 |
| Document: 0001437749-26-020562-index.html | 0001437749-26-020562 |
| Document: 0001437749-26-020562.txt | 0001437749-26-020562 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $0.6885 | awaiting T+20 | — | $0.6483 (−5.84%) |
Sep 22, 2026 5w ago | 8-K | $1.03 $0.6900 | ▼ −33.01% | ▼ −32.45% | $0.6483 (−37.06%) |
Sep 18, 2026 5w ago | 8-K | $0.7395 $0.6820 | ▲ +7.78% | ▲ +6.87% | $0.6483 (+12.33%) |
Jul 29, 2026 12w ago | 8-K | $0.8696 $0.9244 | ▲ +6.30% | ▲ +1.28% | $0.6483 (−25.45%) |
Jun 15, 2026 19w ago | 8-K | $1.21 $1.15 | ▼ −4.96% | ▼ −4.21% | $0.6483 (−46.42%) |
May 7, 2026 24w ago | 8-K | $1.36 $1.36 | · 0.00% | ▲ +3.14% | $0.6483 (+52.33%) |
May 7, 2026 24w ago | Press Release | $1.36 $1.36 | · 0.00% | ▼ −3.14% | $0.6483 (−52.33%) |
Mar 12, 2026 32w ago | Press Release | $1.95 $1.64 | ▲ +15.90% | ▲ +17.87% | $0.6483 (+66.75%) |
Mar 10, 2026 33w ago | 8-K | $2.38 $1.70 | ▼ −28.57% | ▼ −28.42% | $0.6483 (−72.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers